Bio-Rad's Q3 revenue comes slightly above estimates on Clinical Diagnostics growth

Bio-Rad Laboratories

04/11/2026 22:15

Overview
Life science and diagnostics provider's Q3 revenue rose 0.5% yr/yr, led by Clinical Diagnostics
Adjusted EPS for Q3 increased to $2.65 from $2.26 a year earlier
Net income swung to a profit, driven by gain on Sartorius AG investment

Outlook
Bio-Rad expects 2026 non-GAAP, currency-neutral revenue to range from down 3% to up 0.5%
Company maintains 2026 non-GAAP operating margin outlook at 10% to 12%

Result Drivers
CLINICAL DIAGNOSTICS GROWTH - Higher sales in Clinical Diagnostics segment, particularly in quality systems and diabetes products, drove overall revenue growth
DROPLET DIGITAL PCR DEMAND - Increased demand for Droplet Digital PCR instruments partially offset declines in Life Science segment sales
PROCESS CHROMATOGRAPHY WEAKNESS - Lower process chromatography sales and challenges in the academic research market weighed on Life Science segment revenue

Company press release: ID:nBw5QcnQVa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Slight Beat*
$656.40 mln
$649.95 mln (2 Analysts)
Q3 EPS
 
$17.02
 
Q3 Net Income
 
$458.60 mln
 
Q3 Gross Margin
 
50.10%
 
Q3 EBIT Margin
 
-7.60%
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Bio-Rad Laboratories, Inc. is $362.50, about 3.3% below its November 3 closing price of $374.91
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 35 three months ago

Reuters Recommended Reads
Nov 3 - Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates
Nov 4 - Bruker Q3 revenue tops estimates on US academic unit strength
Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)